University of Michigan Data Coordinating Center for the Diabetic Foot Consortium

糖尿病相关足溃疡（DFU）是糖尿病的常见和破坏性并发症， FDA批准的疗法。糖尿病足联盟（DFC）成立于2018年，是第一个多站点 美国临床研究致力于阐明促进DFU愈合和预防复发的生物标志物。的 导致不良结局的已知因素的多样性和复杂性需要经验的多样性 四个DFC临床研究单位（CRU）、生物标志物分析单位（BAU）和 密歇根大学（UM）数据协调中心（DCC），以实现DFC的科学目标。 DCC带来了超过23年的复杂的统计和业务领导经验 研究和网络，利用糖尿病并发症和共病建模方面的具体经验， 慢性疾病的设计和分析，生物标志物的发现和验证，以及FDA的合作。的 DCC在这些领域的领导地位补充了DFC的临床和实验室专业知识。我们一起 将确定重要和可靠的生物标志物，预测DFU愈合和复发，并研究 患者和医生特征与良好DFU结局的相关性。在我们的前三年，DCC已经 与CRU和BAU研究人员以及NIDDK科学家建立了成功和持久的合作伙伴关系， 两项生物标志物验证研究和一项收集生物标本供未来研究的生物储存研究。我们 将继续这种伙伴关系，以完成这些复杂的研究，并最终确定一个平台研究的患者， 开放的DFU，将支持未来的生物标志物研究，以及进一步了解标准的影响， 护理疗法和健康的社会决定因素对DFU结果的影响。这些活动将奠定基础 用于未来的试验，为DFU患者提供更好的护理和健康结果。 我们将通过以下方式实现这些目标：1）提供量身定制的基础设施和服务， 负责所有DFC研究的管理和运营，并促进DFC之间的有效沟通 2）确保收集及时、准确和可复制的数据， 通过提供专业的统计设计、高效的 数据库架构和有效的研究协调; 3）应用最先进的生物信息学， 分析生物标志物资格的统计方法，以检测相关的重要患者特征 具有良好的临床结局，并确定可检验的假设，以指导患者亚群的护理 关于DFU由一个经验丰富、成就卓著的UM DCC完成这些目标将导致 将经验证的生物标志物从实验室转化为床旁，并改善基于 全面的患者、足部溃疡和治疗数据。CRU、BAU、卫星站点之间的协作， 辅助研究者、NIDDK和DCC将最大限度地发挥联盟的科学和临床影响 在这个复杂而富有挑战性的治疗领域。

Diabetes-related foot ulcers (DFUs) are prevalent and devastating complications of diabetes, with few FDA-approved therapies. The Diabetic Foot Consortium (DFC) was established in 2018 as the first multi-site US clinical research effort to elucidate biomarkers that promote DFU healing and prevent recurrence. The multiplicity and complexity of known factors contributing to poor outcomes require the diversity of experience and expertise of the four DFC clinical research units (CRUs), the biomarker analysis units (BAUs), and the University of Michigan (UM) data coordinating center (DCC) to achieve the scientific objectives of the DFC. The DCC brings over 23 years of experience in statistical and operational leadership of complex studies and networks, leveraging specific experience in diabetes complications and co-morbidity modeling, design and analysis of chronic diseases, biomarker discovery and validation, and FDA collaborations. The DCC’s leadership in these areas complements the clinical and laboratory expertise of the DFC. Together we will identify important and reliable biomarkers that predict DFU healing and recurrence and study the association of patient and physician characteristics with good DFU outcomes. In our first 3 years, the DCC has built successful and durable partnerships with CRU and BAU investigators and NIDDK scientists to implement two biomarker validation studies and a biorepository study that collects biospecimens for future research. We will continue this partnership to complete these complex studies and finalize a platform study in patients with open DFUs that will support future biomarker studies, as well further our knowledge of the impact of standard of care therapies and social determinants of health on DFU outcomes. These activities will lay the foundation for future trials leading to better care and health outcomes for patients with DFUs. We will accomplish these goals by: 1) providing tailored infrastructure and services to ensure seamless administration and operations for all DFC studies and facilitate effective communication among DFC stakeholders; 2) ensuring the collection of timely, accurate and reproducible data and high-quality biospecimens and maximizing adherence to study protocols by providing expert statistical design, efficient database architecture, and effective study coordination; 3) applying state-of-the-art bioinformatics and statistical methods to analyze biomarker qualification, to detect important patient characteristics associated with good clinical outcomes, and to identify testable hypotheses to guide care for subpopulations of patients with DFUs. Completion of these aims by a highly experienced and accomplished UM DCC will result in translation of the validated biomarkers from bench to bedside, and improvements in standard of care based on comprehensive patient, foot ulcer and treatment data. Collaboration among the CRUs, BAUs, satellite sites, ancillary study investigators, NIDDK and DCC will maximize the scientific and clinical impact of the Consortium in this complex and challenging therapeutic area.